nach oben

Erschienen in:

01.10.2015 | Research Paper

Assessment of methylation status of locoregional lymph nodes in lung cancer using EBUS-NA

verfasst von: Laura Millares, Mireia Serra, Felipe Andreo, Jose Sanz-Santos, Concepción Montón, Carles Grimau, Miguel Gallego, Laia Setó, Neus Combalia, Mariona Llatjos, Rosa Escoda, Eva Castellà, Eduard Monsó

Erschienen in: Clinical & Experimental Metastasis | Ausgabe 7/2015

Einloggen, um Zugang zu erhalten

Abstract

Hypermethylation of the promoter region of tumor suppressor genes is associated with carcinogenesis in lung cancer (LC). Endobronchial ultrasound with needle aspiration (EBUS-NA) is a semi-invasive method for obtaining cell blocks from lymph nodes, which can be used for epigenetic analyses. To establish the relationship between methylation status of p16, DAPK, RASSF1a, APC and CDH13 genes in lymph nodes sampled by EBUS-NA, tumor staging and prognosis. Methylation status of DAPK, p16, RASSF1a, APC and CDH13 genes was assessed in EBUS-NA cell blocks from LC patients and related to stage and survival. Eighty-five consecutive patients [mean age 67 (SD 8)] were included. Methylation of ≥1 gene was found in 43 malignant nodes (67 %). A higher prevalence of RASSF1a methylation was observed in small cell lung cancer patients [9/10 (90 %) vs. 15/53 (28 %); p < 0.001 χ² test]. Methylation of APC and/or p16 was related to advanced staging in non-small cell lung cancer (NSCLC) [15/29 (52 %) vs. 6/24 (25 %), p = 0.048, χ² test]. Patients with NSCLC showing methylation of APC and/or p16 had also lower 6-month survival (p = 0.019, log rank test), which persisted after adjustment for age and subtyping (HR = 6, 95 % CI [1.8–19.5], p = 0.003, Cox regression). Epigenetic analyses are feasible in EBUS-NA cell blocks and may identify methylation patterns associated with worse prognosis. Methylation of p16 and APC genes in NSCLC patients was associated with advanced staging and lower 6-month survival.

Nur mit Berechtigung zugänglich

Globocan (2012) Home. http://globocan.iarc.fr/Default.aspx. Accessed 10 Jul 2014

Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63:11–30. doi:10.3322/caac.21166 CrossRefPubMed

Youlden DR, Cramb SM, Baade PD (2008) The international epidemiology of lung cancer: geographical distribution and secular trends. J Thorac Oncol 3:819–831. doi:10.1097/JTO.0b013e31818020eb CrossRefPubMed

Kratz JR, Jablons DM (2009) Genomic prognostic models in early-stage lung cancer. Clin Lung Cancer 10:151–157. doi:10.3816/CLC.2009.n.021 CrossRefPubMed

Langevin SM, Kratzke RA, Kelsey KT (2014) Epigenetics of lung cancer. Transl Res J Lab Clin Med. doi:10.1016/j.trsl.2014.03.001

Darwiche K, Zarogoulidis P, Baehner K et al (2013) Assessment of SHOX2 methylation in EBUS-TBNA specimen improves accuracy in lung cancer staging. Ann Oncol 24:2866–2870. doi:10.1093/annonc/mdt365 CrossRefPubMed

Belinsky SA, Liechty KC, Gentry FD et al (2006) Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort. Cancer Res 66:3338–3344. doi:10.1158/0008-5472.CAN-05-3408 CrossRefPubMed

Belinsky SA (2005) Silencing of genes by promoter hypermethylation: key event in rodent and human lung cancer. Carcinogenesis 26:1481–1487. doi:10.1093/carcin/bgi020 CrossRefPubMed

Belinsky SA, Nikula KJ, Palmisano WA et al (1998) Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci USA 95:11891–11896CrossRefPubMedCentralPubMed

10.

Licchesi JDF, Westra WH, Hooker CM, Herman JG (2008) Promoter hypermethylation of hallmark cancer genes in atypical adenomatous hyperplasia of the lung. Clin Cancer Res 14:2570–2578. doi:10.1158/1078-0432.CCR-07-2033 CrossRefPubMed

11.

Belinsky SA (2015) Unmasking the lung cancer epigenome. Annu Rev Physiol 77:453–474. doi:10.1146/annurev-physiol-021014-072018 CrossRefPubMed

12.

Lin Q, Geng J, Ma K et al (2009) RASSF1A, APC, ESR1, ABCB1 and HOXC9, but not p16INK4A, DAPK1, PTEN and MT1G genes were frequently methylated in the stage I non-small cell lung cancer in China. J Cancer Res Clin Oncol 135:1675–1684. doi:10.1007/s00432-009-0614-4 CrossRefPubMed

13.

Dammann R, Li C, Yoon JH et al (2000) Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet 25:315–319. doi:10.1038/77083 CrossRefPubMed

14.

Licchesi JDF, Westra WH, Hooker CM et al (2008) Epigenetic alteration of Wnt pathway antagonists in progressive glandular neoplasia of the lung. Carcinogenesis 29:895–904. doi:10.1093/carcin/bgn017 CrossRefPubMedCentralPubMed

15.

Fukui T, Kondo M, Ito G et al (2005) Transcriptional silencing of secreted frizzled related protein 1 (SFRP 1) by promoter hypermethylation in non-small-cell lung cancer. Oncogene 24:6323–6327. doi:10.1038/sj.onc.1208777 CrossRefPubMed

16.

Mazieres J, He B, You L et al (2004) Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer. Cancer Res 64:4717–4720. doi:10.1158/0008-5472.CAN-04-1389 CrossRefPubMed

17.

Kim DH, Nelson HH, Wiencke JK et al (2001) Promoter methylation of DAP-kinase: association with advanced stage in non-small cell lung cancer. Oncogene 20:1765–1770. doi:10.1038/sj.onc.1204302 CrossRefPubMed

18.

Tang X, Khuri FR, Lee JJ et al (2000) Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small-cell lung cancer. J Natl Cancer Inst 92:1511–1516CrossRefPubMed

19.

Toyooka S, Toyooka KO, Miyajima K et al (2003) Epigenetic down-regulation of death-associated protein kinase in lung cancers. Clin Cancer Res 9:3034–3041PubMed

20.

Raveh T, Droguett G, Horwitz MS et al (2001) DAP kinase activates a p19ARF/p53-mediated apoptotic checkpoint to suppress oncogenic transformation. Nat Cell Biol 3:1–7. doi:10.1038/35050500 CrossRefPubMed

21.

Brock MV, Hooker CM, Ota-Machida E et al (2008) DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med 358:1118–1128. doi:10.1056/NEJMoa0706550 CrossRefPubMed

22.

Agathanggelou A, Honorio S, Macartney DP et al (2001) Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours. Oncogene 20:1509–1518. doi:10.1038/sj.onc.1204175 CrossRefPubMed

23.

Honorio S, Agathanggelou A, Schuermann M et al (2003) Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patients. Oncogene 22:147–150. doi:10.1038/sj.onc.1206057 CrossRefPubMed

24.

25.

Benlloch S, Galbis-Caravajal JM, Alenda C et al (2009) Expression of molecular markers in mediastinal nodes from resected stage I non-small-cell lung cancer (NSCLC): prognostic impact and potential role as markers of occult micrometastases. Ann Oncol 20:91–97. doi:10.1093/annonc/mdn538 CrossRefPubMed

26.

Adams K, Shah PL, Edmonds L, Lim E (2009) Test performance of endobronchial ultrasound and transbronchial needle aspiration biopsy for mediastinal staging in patients with lung cancer: systematic review and meta-analysis. Thorax 64:757–762. doi:10.1136/thx.2008.109868 CrossRefPubMed

27.

Varela-Lema L, Fernández-Villar A, Ruano-Ravina A (2009) Effectiveness and safety of endobronchial ultrasound-transbronchial needle aspiration: a systematic review. Eur Respir J 33:1156–1164. doi:10.1183/09031936.00097908 CrossRefPubMed

28.

Sanz-Santos J, Serra M, Gallego M et al (2014) Determinants of false-negative results in non-small-cell lung cancer staging by endobronchial ultrasound-guided needle aspiration. Eur J Cardio-Thorac Surg. doi:10.1093/ejcts/ezu253

29.

Nakajima T, Yasufuku K, Suzuki M et al (2007) Assessment of epidermal growth factor receptor mutation by endobronchial ultrasound-guided transbronchial needle aspiration. Chest 132:597–602. doi:10.1378/chest.07-0095 CrossRefPubMed

30.

Garcia-Olivé I, Monsó E, Andreo F et al (2010) Endobronchial ultrasound-guided transbronchial needle aspiration for identifying EGFR mutations. Eur Respir J 35:391–395. doi:10.1183/09031936.00028109 CrossRefPubMed

31.

Sanz-Santos J, Andreo F, Sánchez D et al (2010) Usefulness of a lung cancer rapid diagnosis specialist clinic. Contribution of ultrasound bronchoscopy. Arch Bronconeumol 46:640–645. doi:10.1016/j.arbres.2010.07.005 CrossRefPubMed

32.

De Leyn P, Lardinois D, Van Schil PE et al (2007) ESTS guidelines for preoperative lymph node staging for non-small cell lung cancer. Eur J Cardio-Thorac Surg 32:1–8. doi:10.1016/j.ejcts.2007.01.075 CrossRef

33.

Cerfolio RJ, Bryant AS (2007) Ratio of the maximum standardized uptake value on FDG-PET of the mediastinal (N2) lymph nodes to the primary tumor may be a universal predictor of nodal malignancy in patients with nonsmall-cell lung cancer. Ann Thorac Surg 83:1826–1829. doi:10.1016/j.athoracsur.2006.12.034 (discussion 1829–1830) CrossRefPubMed

34.

Du Rand IA, Barber PV, Goldring J et al (2011) British Thoracic Society guideline for advanced diagnostic and therapeutic flexible bronchoscopy in adults. Thorax 66(3):1–21. doi:10.1136/thoraxjnl-2011-200713 CrossRef

35.

Garcia-Olivé I, Monsó E, Andreo F et al (2009) Sensitivity of linear endobronchial ultrasonography and guided transbronchial needle aspiration for the identification of nodal metastasis in lung cancer staging. Ultrasound Med Biol 35:1271–1277. doi:10.1016/j.ultrasmedbio.2009.03.007 CrossRefPubMed

36.

Lee HS, Lee GK, Lee H-S et al (2008) Real-time endobronchial ultrasound-guided transbronchial needle aspiration in mediastinal staging of non-small cell lung cancer: how many aspirations per target lymph node station? Chest 134:368–374. doi:10.1378/chest.07-2105 CrossRefPubMed

37.

Nayak A, Sugrue C, Koenig S et al (2012) Endobronchial ultrasound-guided transbronchial needle aspirate (EBUS-TBNA): a proposal for on-site adequacy criteria. Diagn Cytopathol 40:128–137. doi:10.1002/dc.21517 CrossRefPubMed

38.

Alsharif M, Andrade RS, Groth SS et al (2008) Endobronchial ultrasound-guided transbronchial fine-needle aspiration: the University of Minnesota experience, with emphasis on usefulness, adequacy assessment, and diagnostic difficulties. Am J Clin Pathol 130:434–443. doi:10.1309/BLLQF8KDHWW6MJNQ CrossRefPubMed

39.

Du Rand IA, Blaikley J, Booton R et al (2013) British thoracic society guideline for diagnostic flexible bronchoscopy in adults: accredited by NICE. Thorax 68(Suppl 1):i1–i44. doi:10.1136/thoraxjnl-2013-203618 CrossRefPubMed

40.

Nakajima T, Yasufuku K (2011) How I do it–optimal methodology for multidirectional analysis of endobronchial ultrasound-guided transbronchial needle aspiration samples. J Thorac Oncol 6:203–206. doi:10.1097/JTO.0b013e318200f496 CrossRefPubMed

41.

Sanz-Santos J, Serra P, Andreo F et al (2012) Contribution of cell blocks obtained through endobronchial ultrasound-guided transbronchial needle aspiration to the diagnosis of lung cancer. BMC Cancer 12:34. doi:10.1186/1471-2407-12-34 CrossRefPubMedCentralPubMed

42.

Esterbrook G, Anathhanam S, Plant PK (2013) Adequacy of endobronchial ultrasound transbronchial needle aspiration samples in the subtyping of non-small cell lung cancer. Lung Cancer 80:30–34. doi:10.1016/j.lungcan.2012.12.017 CrossRefPubMed

43.

Navani N, Brown JM, Nankivell M et al (2012) Suitability of endobronchial ultrasound-guided transbronchial needle aspiration specimens for subtyping and genotyping of non-small cell lung cancer: a multicenter study of 774 patients. Am J Respir Crit Care Med 185:1316–1322. doi:10.1164/rccm.201202-0294OC CrossRefPubMedCentralPubMed

44.

Goldstraw P (2009) Staging manual in thoracic oncology. RX Press, Orange Park

45.

Goldstraw P, Crowley J, Chansky K et al (2007) The IASLC lung cancer staging project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2:706–714. doi:10.1097/JTO.0b013e31812f3c1a CrossRefPubMed

46.

Yung RCW, Otell S, Illei P et al (2012) Improvement of cellularity on cell block preparations using the so-called tissue coagulum clot method during endobronchial ultrasound-guided transbronchial fine-needle aspiration. Cancer Cytopathol 120:185–195. doi:10.1002/cncy.20199 CrossRefPubMed

47.

Hirsch FR, Wynes MW, Gandara DR, Bunn PA (2010) The tissue is the issue: personalized medicine for non-small cell lung cancer. Clin Cancer Res 16:4909–4911. doi:10.1158/1078-0432.CCR-10-2005 CrossRefPubMed

48.

Almeida FA (2012) Bronchoscopy and endobronchial ultrasound for diagnosis and staging of lung cancer. Cleve Clin J Med 79(1):S11–S16. doi:10.3949/ccjm.79.s2.03

49.

Plönes T, Elze M, Kayser G et al (2014) mRNA and miRNA analyses in cytologically positive endobronchial ultrasound-guided transbronchial needle aspiration: implications for molecular staging in lung cancer patients. Cancer Cytopathol 122:292–298. doi:10.1002/cncy.21398 CrossRefPubMed

50.

Kinsey CM, Arenberg DA (2014) Endobronchial ultrasound-guided transbronchial needle aspiration for non-small cell lung cancer staging. Am J Respir Crit Care Med 189:640–649. doi:10.1164/rccm.201311-2007CI CrossRefPubMed

51.

Leiro-Fernández V, De Chiara L, Botana-Rial M et al (2014) Viability of lymph node samples obtained by echobronchoscopy in the study of epigenetic alterations in patients with lung cancer. Arch Bronconeumol 50:213–220. doi:10.1016/j.arbres.2013.11.017 PubMed

52.

Nakajima T, Yasufuku K, Suzuki M et al (2009) Assessment of chemosensitivity-related aberrant methylation of nonsmall cell lung cancer by EBUS-TBNA. J Bronchol Interv Pulmonol 16:10–14. doi:10.1097/LBR.0b013e318195d930 CrossRef

53.

Schuurbiers OCJ, Looijen-Salamon MG, Ligtenberg MJL, van der Heijden HFM (2010) A brief retrospective report on the feasibility of epidermal growth factor receptor and KRAS mutation analysis in transesophageal ultrasound- and endobronchial ultrasound-guided fine needle cytological aspirates. J Thorac Oncol 5:1664–1667. doi:10.1097/JTO.0b013e3181f0bd93 CrossRefPubMed

54.

Reynolds JP, Tubbs RR, Minca EC et al (2014) EGFR mutational genotyping of liquid based cytology samples obtained via fine needle aspiration (FNA) at endobronchial ultrasound of non-small cell lung cancer (NSCLC). Lung Cancer. doi:10.1016/j.lungcan.2014.09.003 PubMed

55.

Folch E, Yamaguchi N, VanderLaan PA et al (2013) Adequacy of lymph node transbronchial needle aspirates using convex probe endobronchial ultrasound for multiple tumor genotyping techniques in non-small-cell lung cancer. J Thorac Oncol 8:1438–1444. doi:10.1097/JTO.0b013e3182a471a9 CrossRefPubMedCentralPubMed

56.

Pellisé M, Castells A, Ginès A et al (2004) Detection of lymph node micrometastases by gene promoter hypermethylation in samples obtained by endosonography-guided fine-needle aspiration biopsy. Clin Cancer Res 10:4444–4449. doi:10.1158/1078-0432.CCR-03-0600 CrossRefPubMed

57.

Toyooka S, Toyooka KO, Maruyama R et al (2001) DNA methylation profiles of lung tumors. Mol Cancer Ther 1:61–67PubMed

58.

Yanagawa N, Tamura G, Oizumi H et al (2003) Promoter hypermethylation of tumor suppressor and tumor-related genes in non-small cell lung cancers. Cancer Sci 94:589–592CrossRefPubMed

59.

Harden SV, Tokumaru Y, Westra WH et al (2003) Gene promoter hypermethylation in tumors and lymph nodes of stage I lung cancer patients. Clin Cancer Res 9:1370–1375PubMed

60.

Gu J, Berman D, Lu C et al (2006) Aberrant promoter methylation profile and association with survival in patients with non-small cell lung cancer. Clin Cancer Res 12:7329–7338. doi:10.1158/1078-0432.CCR-06-0894 CrossRefPubMed

61.

Hawes SE, Stern JE, Feng Q et al (2010) DNA hypermethylation of tumors from non-small cell lung cancer (NSCLC) patients is associated with gender and histologic type. Lung Cancer 69:172–179. doi:10.1016/j.lungcan.2009.11.002 CrossRefPubMedCentralPubMed

62.

Yanagawa N, Tamura G, Oizumi H et al (2007) Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers. Lung Cancer 58:131–138. doi:10.1016/j.lungcan.2007.05.011 CrossRefPubMed

63.

Zöchbauer-Müller S, Fong KM, Virmani AK et al (2001) Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res 61:249–255PubMed

64.

Belinsky SA, Palmisano WA, Gilliland FD et al (2002) Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. Cancer Res 62:2370–2377PubMed

65.

Kim DH, Nelson HH, Wiencke JK et al (2001) p16(INK4a) and histology-specific methylation of CpG islands by exposure to tobacco smoke in non-small cell lung cancer. Cancer Res 61:3419–3424PubMed

66.

Guo S, Tan L, Pu W et al (2014) Quantitative assessment of the diagnostic role of APC promoter methylation in non-small cell lung cancer. Clin Epigenetics 6:5. doi:10.1186/1868-7083-6-5 CrossRefPubMedCentralPubMed

67.

Usadel H, Brabender J, Danenberg KD et al (2002) Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer. Cancer Res 62:371–375PubMed

68.

Toyooka S, Suzuki M, Maruyama R et al (2004) The relationship between aberrant methylation and survival in non-small-cell lung cancers. Br J Cancer 91:771–774. doi:10.1038/sj.bjc.6602013 PubMedCentralPubMed

69.

Wang J, Lee JJ, Wang L et al (2004) Value of p16INK4a and RASSF1A promoter hypermethylation in prognosis of patients with resectable non-small cell lung cancer. Clin Cancer Res 10:6119–6125. doi:10.1158/1078-0432.CCR-04-0652 CrossRefPubMed

70.

Brabender J, Usadel H, Danenberg KD et al (2001) Adenomatous polyposis coli gene promoter hypermethylation in non-small cell lung cancer is associated with survival. Oncogene 20:3528–3532. doi:10.1038/sj.onc.1204455 CrossRefPubMed

71.

Drilon A, Sugita H, Sima CS et al (2014) A prospective study of tumor suppressor gene methylation as a prognostic biomarker in surgically resected stage I to IIIA non-small-cell lung cancers. J Thorac Oncol 9:1272–1277. doi:10.1097/JTO.0000000000000256 CrossRefPubMedCentralPubMed

72.

Esteller M, Sanchez-Cespedes M, Rosell R et al (1999) Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res 59:67–70PubMed

73.

Laird PW (2003) The power and the promise of DNA methylation markers. Nat Rev Cancer 3:253–266. doi:10.1038/nrc1045 CrossRefPubMed

74.

Begum S, Brait M, Dasgupta S et al (2011) An epigenetic marker panel for detection of lung cancer using cell-free serum DNA. Clin Cancer Res 17:4494–4503. doi:10.1158/1078-0432.CCR-10-3436 CrossRefPubMedCentralPubMed

75.

Hubers AJ, Prinsen CFM, Sozzi G et al (2013) Molecular sputum analysis for the diagnosis of lung cancer. Br J Cancer 109:530–537. doi:10.1038/bjc.2013.393 CrossRefPubMedCentralPubMed

76.

Hubers AJ, Heideman DAM, Burgers SA et al (2015) DNA hypermethylation analysis in sputum for the diagnosis of lung cancer: training validation set approach. Br J Cancer 112:1105–1113. doi:10.1038/bjc.2014.636 CrossRefPubMed

Titel: Assessment of methylation status of locoregional lymph nodes in lung cancer using EBUS-NA
verfasst von: Laura Millares
Mireia Serra
Felipe Andreo
Jose Sanz-Santos
Concepción Montón
Carles Grimau
Miguel Gallego
Laia Setó
Neus Combalia
Mariona Llatjos
Rosa Escoda
Eva Castellà
Eduard Monsó
Publikationsdatum: 01.10.2015
Verlag: Springer Netherlands
Erschienen in: Clinical & Experimental Metastasis / Ausgabe 7/2015
Print ISSN: 0262-0898
Elektronische ISSN: 1573-7276
DOI: https://doi.org/10.1007/s10585-015-9733-2

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Assessment of methylation status of locoregional lymph nodes in lung cancer using EBUS-NA

Abstract

Neu im Fachgebiet Onkologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Update Onkologie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2015

Analysis of radiation therapy in a model of triple-negative breast cancer brain metastasis

Human breast cancer bone metastasis in vitro and in vivo: a novel 3D model system for studies of tumour cell-bone cell interactions

Activity of T-DM1 in Her2-positive breast cancer brain metastases

Cellular fibronectin 1 promotes VEGF-C expression, lymphangiogenesis and lymph node metastasis associated with human oral squamous cell carcinoma

Suppression of lung metastases by the CD26/DPP4 inhibitor Vildagliptin in mice

An orthotopic xenograft model with survival hindlimb amputation allows investigation of the effect of tumor microenvironment on sarcoma metastasis

Neu im Fachgebiet Onkologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Update Onkologie